Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3731 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Micromet licenses cancer drug to Tracon

Tracon will pay Micromet upfront and milestone payments of more than $100 million, if D93 is successfully developed and commercialized. In addition, Micromet will receive royalties on worldwide

Hollis-Eden drops radiation sickness drug

The Department of Health and Human Services (HHS) told the drug developer that the amount of data available for Neumune was not sufficient to justify the advance purchase

Exelixis submits IND for cancer drug

The drug is a small molecule inhibitor of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting tumor cell growth, survival, and resistance

Lilly withdraws EU Arxxant application

The news follows an announcement from the FDA that it would still need an additional three-year study on the drug before approval in the US, rejecting an appeal

FDA strengthens warnings on sleep drugs

Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event. Along with the labeling revisions, the